Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, February 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 194 articles:
HTML format


 

Single Articles

  1. WHONGSIRI P, Pimratana C, Wijitsettakul U, Sanpavat A, et al
    Oxidative stress and LINE-1 reactivation in bladder cancer are epigenetically linked through active chromatin formation.
    Free Radic Biol Med. 2019 Jan 28. pii: S0891-5849(18)32321.
    Abstract    

    Abstract available

  2. ANDREW AS, Karagas MR, Schroeck FR, Marsit CJ, et al
    MicroRNA dysregulation and non-muscle invasive bladder cancer prognosis.
    Cancer Epidemiol Biomarkers Prev. 2019 Jan 30. pii: 1055-9965.EPI-18-0884.
    Abstract    

    Abstract available

  3. RAVEN PA, D'Costa NM, Moskalev I, Tan Z, et al
    Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.
    Am J Clin Exp Urol. 2018;6:245-259.
    Abstract    

    Abstract available

  4. MENG XY, Shi MJ, Zeng ZH, Chen C, et al
    The Role of COL5A2 in Patients With Muscle-Invasive Bladder Cancer: A Bioinformatics Analysis of Public Datasets Involving 787 Subjects and 29 Cell Lines.
    Front Oncol. 2019;8:659.
    Abstract    

    Abstract available

  5. DOMINGOS-PEREIRA S, Sathiyanadan K, La Rosa S, Polak L, et al
    Intravesical Ty21a vaccine promotes dendritic cells and T cell-mediated tumor regression in the MB49 bladder cancer model.
    Cancer Immunol Res. 2019 Jan 29. pii: 2326-6066.CIR-18-0671.
    Abstract    

    Abstract available

  6. FONT A, Luque R, Villa JC, Domenech M, et al
    The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).
    Target Oncol. 2019 Jan 29. pii: 10.1007/s11523-019-00619.
    Abstract    

    Abstract available

  7. RAMAKRISHNAN S, Granger V, Rak M, Hu Q, et al
    Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
    Cell Death Differ. 2019 Jan 28. pii: 10.1038/s41418-019-0278.
    Abstract    

    Abstract available

  8. VISNJAR T, Romih R, Zupancic D
    Lectins as possible tools for improved urinary bladder cancer management.
    Glycobiology. 2019 Jan 25. pii: 5301307. doi: 10.1093.
    Abstract    

    Abstract available

  9. SHI S, Tian B
    Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis.
    Cancer Biomark. 2019 Jan 18. pii: CBM181940. doi: 10.3233/CBM-181940.
    Abstract    

    Abstract available

  10. LOH-DOYLE JC
    Penile Implant Considerations in the Bladder Cancer Survivor.
    Curr Urol Rep. 2019;20:7.
    Abstract    

    Abstract available

  11. BIELLI P, Di Stasi SM, Sette C
    The emerging role of PTBP1 in human cancer: novel prognostic factor in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  12. PATHAK RA, Hemal AK
    Frailty and sarcopenia impact surgical and oncologic outcomes after radical cystectomy in patients with bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  13. SORIA F, Shariat SF
    Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers.
    Transl Androl Urol. 2018;7.
    Abstract    



  14. NIEGISCH G
    Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
    Transl Androl Urol. 2018;7.
    Abstract    



  15. PICHLER R, Loidl W, Pichler M
    High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  16. KAAG MG, Raman JD
    Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  17. BATURA D
    Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  18. AJIB K, Kulkarni GS
    Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  19. MAHENDRAN R
    Do we have all the facts to determine the impact of bacillus Calmette-Guerin therapy on bladder cancer?
    Transl Androl Urol. 2018;7.
    Abstract    



  20. LEE KH, Ku JH
    Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors.
    Transl Androl Urol. 2018;7.
    Abstract    



  21. DAL MORO F, Colicchia M
    Does obesity impact bladder cancer prognosis?-a long-lasting debate.
    Transl Androl Urol. 2018;7.
    Abstract    



  22. OOSTERLINCK W, Decaestecker K
    An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers.
    Transl Androl Urol. 2018;7.
    Abstract    



  23. VRIELING A
    The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  24. BRODIE A, McCauley N, Cresswell J, Vasdev N, et al
    T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate.
    Transl Androl Urol. 2018;7.
    Abstract    



  25. ROSSER CJ
    Nutritional implications for quality of life in bladder cancer survivors.
    Transl Androl Urol. 2018;7.
    Abstract    



  26. JIANG DM, Jiang H, Chung PWM, Zlotta AR, et al
    Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019;17:38-45.
    Abstract    

    Abstract available

  27. ABDELRAHMAN AE, Rashed HE, Elkady E, Elsebai EA, et al
    Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
    Ann Diagn Pathol. 2019;39:42-52.
    Abstract    

    Abstract available

  28. LEOW JJ, Bedke J, Chamie K, Collins JW, et al
    SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
    World J Urol. 2019 Jan 25. pii: 10.1007/s00345-018-2606.
    Abstract    

    Abstract available

  29. LORENZATTI HILES G, Cates AL, El-Sawy L, Day KC, et al
    A surgical orthotopic approach for studying the invasive progression of human bladder cancer.
    Nat Protoc. 2019 Jan 25. pii: 10.1038/s41596-018-0112.
    Abstract    

    Abstract available

  30. BLACK PC, Goebell PJ, Kamat AM, Nawroth R, et al
    Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series(1).
    Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003.
    Abstract    

    Abstract available

  31. CHEN L, Long Y, Han Z, Yuan Z, et al
    MicroRNA-101 inhibits cell migration and invasion in bladder cancer via targeting FZD4.
    Exp Ther Med. 2019;17:1476-1485.
    Abstract    

    Abstract available

  32. WANG Y, Xu Z, Wang X
    miRNA-373 promotes urinary bladder cancer cell proliferation, migration and invasion through upregulating epidermal growth factor receptor.
    Exp Ther Med. 2019;17:1190-1195.
    Abstract    

    Abstract available

  33. CHO SK, Su LJ, Mao C, Wolenski CD, et al
    Multifunctional nanoclusters of NaYF4:Yb(3+),Er(3+) upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer.
    Mater Sci Eng C Mater Biol Appl. 2019;97:784-792.
    Abstract    

    Abstract available

  34. HA YS, Kim SW, Chun SY, Chung JW, et al
    Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy.
    BMC Urol. 2019;19:10.
    Abstract    

    Abstract available


  35. [Expert consensus on treatment of intravesical therapy in non-muscle invasive bladder cancer].
    Zhonghua Zhong Liu Za Zhi. 2019;41:42-45.
    Abstract    

    Abstract available

  36. ZHOU J, Yang C, Lu Z, Zhang L, et al
    Primary urothelial carcinoma of the prostate: A rare case report.
    Medicine (Baltimore). 2019;98:e14155.
    Abstract    

    Abstract available

  37. TONG S, Yang Z, Zu X, Li Y, et al
    Anterior versus posterior approach laparoscopic radical cystectomy: a retrospective analysis.
    World J Surg Oncol. 2019;17:9.
    Abstract    

    Abstract available

  38. MARTINI T, Heinkele J, Mayr R, Weis CA, et al
    Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.
    Urol Oncol. 2018;36:530.
    Abstract    

    Abstract available

  39. LALANI AA, Sonpavde GP
    Systemic treatments for metastatic urothelial carcinoma.
    Expert Opin Pharmacother. 2019;20:201-208.
    Abstract    

    Abstract available

  40. GU YQ, Shen WY, Zhou Y, Chen SF, et al
    A pyrazolopyrimidine based fluorescent probe for the detection of Cu(2+) and Ni(2+) and its application in living cells.
    Spectrochim Acta A Mol Biomol Spectrosc. 2019;209:141-149.
    Abstract    

    Abstract available

  41. RIVA G, Mian C, Luchini C, Girolami I, et al
    Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
    Virchows Arch. 2019;474:13-20.
    Abstract    

    Abstract available

  42. MILLER R, Heinlen JE
    Reported rates of clostridium difficile following radical cystectomy in national datasets compared to individual institutions.
    Urol Oncol. 2018;36:526.
    Abstract    

    Abstract available

  43. MURAKAMI M, Kiyota H, Kasai K, Bando S, et al
    Antimicrobial prophylaxis for transurethral resection of bladder tumor: A retrospective comparison of preoperative single-dose administration of piperacillin and tazobactam/piperacillin.
    J Infect Chemother. 2018;24:954-957.
    Abstract    

    Abstract available

  44. LI CY, Dai YX, Chen YJ, Chu SY, et al
    Cancer Risks in Vitiligo Patients: A Nationwide Population-Based Study in Taiwan.
    Int J Environ Res Public Health. 2018;15.
    Abstract    

    Abstract available

  45. KONG V, Taylor A, Chung P, Rosewall T, et al
    Evaluation of resource burden for bladder adaptive strategies: A timing study.
    J Med Imaging Radiat Oncol. 2018;62:861-865.
    Abstract    

    Abstract available

  46. ADHYA AK, Pradhan MR
    Ectopic prostatic tissue presenting as a mucosal tumor in urinary bladder.
    Indian J Pathol Microbiol. 2018;61:452-453.
    Abstract    



  47. LEFFLER AJ, Hostnik ET, Warry EE, Habing GG, et al
    Canine urinary bladder transitional cell carcinoma tumor volume is dependent on imaging modality and measurement technique.
    Vet Radiol Ultrasound. 2018;59:767-776.
    Abstract    

    Abstract available

  48. BURGER M
    Editorial Commentary on Gregers et al.
    Scand J Urol. 2018;52:199.
    Abstract    



  49. MARQUEEN KE, Waingankar N, Sfakianos JP, Mehrazin R, et al
    Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States.
    JNCI Cancer Spectr. 2018;2:pky075.
    Abstract    

    Abstract available

  50. JORGENSEN MS, Oldenburg WA, Murray PM
    Mycotic Aneurysm of the Ulnar Artery Secondary to Bacillus Calmette-Guerin Therapy for Bladder Cancer: A Rare Presentation of Hypothenar Hammer Syndrome.
    J Hand Surg Am. 2019 Feb 4. pii: S0363-5023(18)31479.
    Abstract    

    Abstract available

  51. SOUKUPOVA K, Rudolf E
    Suppression of proliferation and activation of cell death by sodium selenite involves mitochondria and lysosomes in chemoresistant bladder cancer cells.
    J Trace Elem Med Biol. 2019;52:58-67.
    Abstract    

    Abstract available

  52. MARCQ G, Jarry E, Ouzaid I, Hermieu JF, et al
    Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Ther Adv Urol. 2019;11:1756287218823678.
    Abstract    

    Abstract available

  53. RAO A, Patel MR
    A review of avelumab in locally advanced and metastatic bladder cancer.
    Ther Adv Urol. 2019;11:1756287218823485.
    Abstract    

    Abstract available

  54. OSTERMAN CK, Babu DS, Geynisman DM, Lewis B, et al
    Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.
    Oncologist. 2019 Feb 6. pii: theoncologist.2018-0561.
    Abstract    

    Abstract available

  55. DI Y, Chen D, Yu W, Yan L, et al
    Bladder cancer stage-associated hub genes revealed by WGCNA co-expression network analysis.
    Hereditas. 2019;156:7.
    Abstract    

    Abstract available

  56. ZHANG X, Liu X, Jing Z, Bi J, et al
    The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer.
    Cancer Gene Ther. 2019 Feb 6. pii: 10.1038/s41417-019-0085.
    Abstract    

    Abstract available

  57. BOC A, Crisan N, Vesa SC, Coman I, et al
    The impact of minimal invasive surgery on early complications and mortality after radical cystectomy for muscle-invasive urothelial bladder cancer.
    J BUON. 2018;23:104-110.
    Abstract    

    Abstract available

  58. SIGNES-PASTOR AJ, Scot Zens M, Seigne J, Schned A, et al
    Rice Consumption and Incidence of Bladder Cancer in the United States Population.
    Epidemiology. 2019;30:e4-e5.
    Abstract    



  59. RAPHAEL MJ, Booth CM
    Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49(th) parallel.
    Can Urol Assoc J. 2019;13:29-31.
    Abstract    



  60. OGIHARA K, Kikuchi E, Okazaki S, Hagiwara M, et al
    Sulfasalazine may modulate the CD44v9-xCT system and enhance CDDP-induced cytotoxic effects in metastatic bladder cancer.
    Cancer Sci. 2019 Feb 4. doi: 10.1111/cas.13960.
    Abstract    

    Abstract available

  61. TSAI YS, Jou YC, Tsai HT, Shiau AL, et al
    Prothymosin-alpha Enhances PTEN Expression and Binds with TRIM21 to Regulate Keap1/Nrf2 Signaling in Human Bladder Cancer.
    Cancer Sci. 2019 Feb 4. doi: 10.1111/cas.13963.
    Abstract    

    Abstract available

  62. HEIDE T, Maurer A, Eipel M, Knoll K, et al
    Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.
    J Pathol. 2019 Feb 4. doi: 10.1002/path.5250.
    Abstract    

    Abstract available

  63. LEMKE EA, Shah AY
    Management of Advanced Bladder Cancer: An Update.
    J Adv Pract Oncol. 2018;9:410-416.
    Abstract    

    Abstract available

  64. XU C, Zhou J, Wang Y, Wang A, et al
    Inhibition of malignant human bladder cancer phenotypes through the down-regulation of the long non-coding RNA SNHG7.
    J Cancer. 2019;10:539-546.
    Abstract    

    Abstract available

  65. CHEN Y, Liu L, Guo Z, Wang Y, et al
    Lost expression of cell adhesion molecule 1 is associated with bladder cancer progression and recurrence and its overexpression inhibited tumor cell malignant behaviors.
    Oncol Lett. 2019;17:2047-2056.
    Abstract    

    Abstract available

  66. COTRUVO JA, Amato H
    National Trends of Bladder Cancer and Trihalomethanes in Drinking Water: A Review and Multicountry Ecological Study.
    Dose Response. 2019;17:1559325818807781.
    Abstract    

    Abstract available

  67. LIU YN, Zhang H, Zhang L, Cai TT, et al
    Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer.
    Cell Death Dis. 2019;10:50.
    Abstract    

    Abstract available

  68. GUDJONSSON S
    Editorial comment on: The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
    Scand J Urol. 2019 Feb 4:1-2. doi: 10.1080/21681805.2018.1563629.
    Abstract    



  69. HU G, Wang X, Han Y, Wang P, et al
    Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
    EXCLI J. 2018;17:1157-1166.
    Abstract    

    Abstract available

  70. PAK S, You D, Jeong IG, Song C, et al
    Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Jan 9. pii: S1558-7673(19)30008.
    Abstract    

    Abstract available

  71. AL-DAGHMIN A, Alhamss S, Al-Najjar H, Al-Saidi I, et al
    Survival and metastasis in muscle-invasive bladder cancer patients who present with indeterminate pulmonary nodules before treatment.
    Ann Saudi Med. 2019;39:42-47.
    Abstract    

    Abstract available

  72. MINA S, Pardo Munevar CA, Osorio D, Garcia-Perdomo HA, et al
    Life quality evaluation in patients with bladder cancer: A systematic review.
    Actas Urol Esp. 2019 Jan 30. pii: S0210-4806(18)30230.
    Abstract    

    Abstract available

  73. SAFWAT O, Abd-Ellatif RN, Othman TS, Afifi M, et al
    The evolving role of protein disulfide isomerase A3 in Egyptian bladder cancer patients.
    Gene. 2019 Jan 29. pii: S0378-1119(19)30068-X. doi: 10.1016/j.gene.2019.
    Abstract    

    Abstract available

  74. ISHII A, Tei Y, Murakami T, Notohara K, et al
    An unusual case of Abeta2M amyloid deposition in bladder cancer in a non-dialysis patient.
    Pathol Int. 2019 Feb 1. doi: 10.1111/pin.12770.
    Abstract    

    Abstract available

  75. BOSSCHIETER J, Nieuwenhuijzen JA, Hentschel A, van Splunter AP, et al
    A two-gene methylation signature for the diagnosis of bladder cancer in urine.
    Epigenomics. 2019 Feb 1. doi: 10.2217/epi-2018-0094.
    Abstract    

    Abstract available

  76. KATTEPUR AK, Patkar S, Goel M, Ramaswamy A, et al
    Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer.
    J Gastrointest Surg. 2019 Jan 31. pii: 10.1007/s11605-019-04104.
    Abstract    

    Abstract available

  77. YUK HD, Jeong CW, Kwak C, Kim HH, et al
    Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting.
    Front Oncol. 2019;8:642.
    Abstract    

    Abstract available

  78. YANG X, Zhao L, Zhang T, Xi J, et al
    Protosappanin B promotes apoptosis and causes G1 cell cycle arrest in human bladder cancer cells.
    Sci Rep. 2019;9:1048.
    Abstract    

    Abstract available

  79. MATULAY JT, Woldu SL, Lim A, Narayan VM, et al
    The impact of squamous histology on survival in patients with muscle-invasive bladder cancer.
    Urol Oncol. 2019 Jan 28. pii: S1078-1439(19)30021.
    Abstract    

    Abstract available

  80. BURKHARD FC, Thalmann GN
    No survival benefit with extended lymphadenectomy: now what?
    Nat Rev Urol. 2019;16:3-4.
    Abstract    

    Abstract available

  81. KONG V, Kwan M, Chen S, Chung P, et al
    Quantification of interobserver variability in image registration using conebeam CT for partial bladder radiotherapy - A Comparison between Lipiodol and Bladder Wall Surface.
    Br J Radiol. 2018 Nov 1:20180413. doi: 10.1259/bjr.20180413.
    Abstract    

    Abstract available

  82. FROEHNER M, Koch R, Hubler M, Heberling U, et al
    Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy.
    BMC Urol. 2018;18:91.
    Abstract    

    Abstract available

  83. ELKADY N, Sultan M, Elkhouly E
    Evaluation of topoisomerase II, ki-67, and P53 expression in non-muscle-invasive urothelial carcinoma and their clinical significance.
    Indian J Pathol Microbiol. 2018;61:526-531.
    Abstract    

    Abstract available

  84. ADIL K, Popovic M, Cury FL, Faria SL, et al
    Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy.
    Pract Radiat Oncol. 2019;9:24-28.
    Abstract    

    Abstract available

  85. REDMAN JM, Madan RA
    Spotlight on atezolizumab and its potential as an oncology agent.
    Expert Rev Anticancer Ther. 2018;18:719-722.
    Abstract    



  86. FREIFELD Y, Krabbe LM, Clinton TN, Woldu SL, et al
    Therapeutic strategies for upper tract urothelial carcinoma.
    Expert Rev Anticancer Ther. 2018;18:765-774.
    Abstract    

    Abstract available

  87. LIU K, Sun E, Lei M, Li L, et al
    BCG-induced formation of neutrophil extracellular traps play an important role in bladder cancer treatment.
    Clin Immunol. 2019 Feb 13. pii: S1521-6616(18)30633.
    Abstract    

    Abstract available

  88. MONTALBO R, Lozano JJ, Izquierdo L, Ingelmo-Torres M, et al
    Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients.
    Transl Res. 2019 Feb 7. pii: S1931-5244(19)30025.
    Abstract    

    Abstract available

  89. WITZKE KE, Grosserueschkamp F, Jutte H, Horn M, et al
    Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer.
    Am J Pathol. 2019 Feb 9. pii: S0002-9440(18)30739.
    Abstract    

    Abstract available

  90. OEYEN E, Hoekx L, De Wachter S, Baldewijns M, et al
    Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  91. CHUNG J, Kulkarni GS, Morash R, Matthew A, et al
    Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory.
    Support Care Cancer. 2019 Feb 14. pii: 10.1007/s00520-019-4649.
    Abstract    

    Abstract available

  92. SIDDIQUI MR, Railkar R, Sanford T, Crooks DR, et al
    Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT).
    Sci Rep. 2019;9:2084.
    Abstract    

    Abstract available

  93. CAO YP, Sun JY, Li MQ, Dong Y, et al
    Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells.
    Acta Pharmacol Sin. 2019 Feb 14. pii: 10.1038/s41401-018-0205.
    Abstract    

    Abstract available

  94. KULKARNI GS, Black PC, Sridhar SS, Kapoor A, et al
    Canadian Urological Association guideline: Muscle-invasive bladder cancer.
    Can Urol Assoc J. 2019 Jan 31. pii: cuaj.5902. doi: 10.5489/cuaj.5902.
    Abstract    



  95. LIN T, Jin H, Gong L, Yu R, et al
    Surveillance of non-muscle invasive bladder cancer using fluorescence in situ hybridization: Protocol for a systematic review and meta-analysis.
    Medicine (Baltimore). 2019;98:e14573.
    Abstract    

    Abstract available

  96. KISPERT S, Marentette J, McHowat J
    Cigarette smoking promotes bladder cancer via increased platelet-activating factor.
    Physiol Rep. 2019;7:e13981.
    Abstract    

    Abstract available

  97. WU S, Ou T, Xing N, Lu J, et al
    Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer.
    Nat Commun. 2019;10:720.
    Abstract    

    Abstract available

  98. DENG S, He SY, Zhao P, Zhang P, et al
    The role of oncostatin M receptor gene polymorphisms in bladder cancer.
    World J Surg Oncol. 2019;17:30.
    Abstract    

    Abstract available

  99. MAJ M, Kokocha A, Bajek A, Drewa T, et al
    The effects of adipose-derived stem cells on CD133-expressing bladder cancer cells.
    J Cell Biochem. 2019 Feb 11. doi: 10.1002/jcb.28436.
    Abstract    

    Abstract available

  100. DENG Y, Bi R, Guo H, Yang J, et al
    Andrographolide Enhances TRAIL-Induced Apoptosis via p53-Mediated Death Receptors Up-Regulation and Suppression of the NF-small ka, CyrillicB Pathway in Bladder Cancer Cells.
    Int J Biol Sci. 2019;15:688-700.
    Abstract    

    Abstract available

  101. SU Y, Yang W, Jiang N, Shi J, et al
    Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.
    Int J Biol Sci. 2019;15:441-452.
    Abstract    

    Abstract available

  102. XIE R, Chen X, Chen Z, Huang M, et al
    Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM.
    Cancer Lett. 2019 Feb 8. pii: S0304-3835(19)30071.
    Abstract    

    Abstract available

  103. KOSOVA IV, Loran OB, Sinyakova LA, Gundorova LV, et al
    [A prognostic value of level of antiviral antibodies in the development of recurrence of bladder cancer].
    Urologiia. 2018;:86-94.
    Abstract    

    Abstract available

  104. STONE L
    Treatment timing well tolerated in bladder cancer.
    Nat Rev Urol. 2019 Feb 11. pii: 10.1038/s41585-019-0162.
    Abstract    



  105. ELIZALDE BENITO FX, Ucar Terren A, Monzon Alebesque F, Urra Palos M, et al
    Bladder cancer with Indian ink.
    Arch Esp Urol. 2019;72:89-90.
    Abstract    

    Abstract available

  106. GOMEZ RIVAS J, Eguibar Gonzalez A, Tortolero Blanco L, Aguilera Bazan A, et al
    [Usefulness of photodynamic diagnosis in high-grade Bladder Cancer and subsequent BCG failure. Bibliographic review.]
    Arch Esp Urol. 2019;72:2-8.
    Abstract    

    Abstract available

  107. EINSTEIN DJ, Sonpavde G
    Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Curr Treat Options Oncol. 2019;20:12.
    Abstract    

    Abstract available

  108. WITLOX WJA, van Osch FHM, Brinkman M, Jochems S, et al
    An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies.
    Eur J Nutr. 2019 Feb 8. pii: 10.1007/s00394-019-01907.
    Abstract    

    Abstract available

  109. IMAI Y, Noda S, Matsuyama C, Shimizu A, et al
    Sex steroid hormone receptors in bladder cancer: Usefulness in differential diagnosis and implications in histogenesis of bladder cancer.
    Urol Oncol. 2019 Feb 6. pii: S1078-1439(19)30024.
    Abstract    

    Abstract available

  110. KRAJEWSKI W, Zdrojowy R, Kolodziej A
    Purified protein derivative skin test-One swallow does not make a summer: Re: Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction Bacillus Calm
    Urol Oncol. 2019 Feb 5. pii: S1078-1439(19)30025.
    Abstract    



  111. OZAWA M, Suenaga S, Ishii T, Suzuki H, et al
    [PRIMARY MALIGNANT LYMPHOMA OF THE BLADDER DIAGNOSED BY TRANSURETHRAL BLADDER TUMOR RESECTION: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2018;109:45-49.
    Abstract    

    Abstract available

  112. ITO A, Takata R, Matsuo T, Kimura T, et al
    [COMPLETE RESECTION OF URACHAL CARCINOMA WITH SIGMOID COLON INVASION AFTER FOLFOX CHEMOTHERAPY: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2018;109:35-39.
    Abstract    

    Abstract available

  113. MITA K, Kobatake K, Ohara S, Kato M, et al
    [LAPAROSCOPIC RADICAL CYSTECTOMY AT HIROSHIMA CITY ASA HOSPITAL].
    Nihon Hinyokika Gakkai Zasshi. 2018;109:1-6.
    Abstract    

    Abstract available

  114. LEE YL, Lai CR, Yen MS
    Recurrent ovarian mixed germ cell tumor with unusual malignant transformation: a case report.
    J Ovarian Res. 2019;12:2.
    Abstract    

    Abstract available

  115. WANG B, Pan W, Yang M, Yang W, et al
    Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Cancer Sci. 2019;110:489-498.
    Abstract    

    Abstract available

  116. PABO-CARRASCO S, Vallejo-Benitez A, Carmona-Pinelo E, Umbria-Jimenez S, et al
    [Nested variant Transitional Cell Carcinoma. Report of two cases and bibliographic review.]
    Arch Esp Urol. 2018;71:794-799.
    Abstract    

    Abstract available

  117. KONDO E, Maki S, Nii M, Yoshida K, et al
    Long-term survival of a patient with malignant transformation of extragonadal endometriosis treated solely with chemotherapy: A case report.
    J Obstet Gynaecol Res. 2018;44:2186-2189.
    Abstract    

    Abstract available

  118. CLEMENTS MB, Krupski TL, Culp SH
    Robotic-Assisted Surgery for Upper Tract Urothelial Carcinoma: A Comparative Survival Analysis.
    Ann Surg Oncol. 2018;25:2550-2562.
    Abstract    

    Abstract available

  119. CRISCUOLO D, Morra F, Giannella R, Visconti R, et al
    New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
    J Exp Clin Cancer Res. 2019;38:91.
    Abstract    

    Abstract available

  120. KUMAR S, Bhoriwal S, Muduly D, Kar M, et al
    Multimodality management of incidentally detected gall bladder cancer: long term results from a tertiary care cancer centre.
    J Gastrointest Oncol. 2019;10:128-133.
    Abstract    

    Abstract available

  121. KARATZAS A, Tzortzis V
    Lower urinary tract symptoms and bladder cancer in children: The hidden scenario.
    Urol Ann. 2019;11:102-104.
    Abstract    

    Abstract available

  122. KALLIFATIDIS G, Smith DK, Morera DS, Gao J, et al
    beta-Arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer.
    Mol Cancer Ther. 2019 Feb 20. pii: 1535-7163.MCT-18-1167.
    Abstract    

    Abstract available

  123. MORRA F, Merolla F, Criscuolo D, Insabato L, et al
    CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
    J Exp Clin Cancer Res. 2019;38:90.
    Abstract    

    Abstract available

  124. YU H, Wang S, Zhu H, Rao D, et al
    LncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer.
    J Cell Physiol. 2019 Feb 20. doi: 10.1002/jcp.28274.
    Abstract    

    Abstract available

  125. RACIOPPI M, Di Gianfrancesco L, Ragonese M, Palermo G, et al
    Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
    Int Braz J Urol. 2018;45.
    Abstract    

    Abstract available

  126. XU X, You K, Wu B
    Zonula occludens-1 associated nucleic acid binding protein plays an invasion-promoting role in bladder cancer.
    Neoplasma. 2019 Feb 14. pii: 180725N530. doi: 10.4149/neo_2018_180725.
    Abstract    

    Abstract available

  127. SHADPOUR P, Zamani M, Aghaalikhani N, Rashtchizadeh N, et al
    Inflammatory cytokines in bladder cancer.
    J Cell Physiol. 2019 Feb 18. doi: 10.1002/jcp.28252.
    Abstract    

    Abstract available

  128. HU J, Zhou L, Song Z, Xiong M, et al
    The identification of new biomarkers for bladder cancer: A study based on TCGA and GEO datasets.
    J Cell Physiol. 2019 Feb 18. doi: 10.1002/jcp.28208.
    Abstract    

    Abstract available

  129. LI J, Wang AS, Wang S, Wang CY, et al
    LncSNHG14 promotes the development and progression of bladder cancer by targeting miRNA-150-5p.
    Eur Rev Med Pharmacol Sci. 2019;23:1022-1029.
    Abstract    

    Abstract available

  130. CAO HL, Liu ZJ, Huang PL, Yue YL, et al
    lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206.
    Eur Rev Med Pharmacol Sci. 2019;23:1012-1021.
    Abstract    

    Abstract available

  131. KRAJEWSKI W, Rodriguez Faba O, Poletajew S, Palou J, et al
    New predictive nomograms for non-muscle-invasive bladder cancer: it is all about the details.
    World J Urol. 2019 Feb 18. pii: 10.1007/s00345-019-02680.
    Abstract    



  132. TAN Y, Zhang T, Zhou L, Liu S, et al
    MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes.
    Med Sci Monit. 2019;25:1323-1335.
    Abstract    

    Abstract available

  133. CHERUKU RR, Cacaccio J, Durrani F, Tabaczynski WA, et al
    Epidermal Growth Factor Receptor Targeted Multifunctional Photosensitizers for Bladder Cancer Imaging and Photodynamic Therapy.
    J Med Chem. 2019 Feb 18. doi: 10.1021/acs.jmedchem.8b01927.
    Abstract    

    Abstract available

  134. LI S, Zhu Y, Liang Z, Wang X, et al
    Correction: Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer.
    Oncotarget. 2019;10:684.
    Abstract    

    Abstract available

  135. AMARA CS, Vantaku V, Lotan Y, Putluri N, et al
    Recent advances in the metabolomic study of bladder cancer.
    Expert Rev Proteomics. 2019 Feb 16. doi: 10.1080/14789450.2019.1583105.
    Abstract    

    Abstract available

  136. ZHANG G, Ma F, Li L, Li J, et al
    Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex.
    Biochem Pharmacol. 2019;163:133-141.
    Abstract    

    Abstract available

  137. SORIA F, Pisano F, Gontero P, Palou J, et al
    Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.
    World J Urol. 2018;36:1775-1781.
    Abstract    

    Abstract available

  138. MARGULIS AV, Fortuny J, Kaye JA, Calingaert B, et al
    Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom.
    Epidemiology. 2018;29:e41-e42.
    Abstract    



  139. SONPAVDE G, Pond GR, Rosenberg JE, Choueiri TK, et al
    Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
    Clin Genitourin Cancer. 2018;16:e961-e967.
    Abstract    

    Abstract available

  140. HERMANN GG, Mogensen K, Rosthoj S
    Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation: efficacy, safety and economic analysis.
    Scand J Urol. 2018;52:194-198.
    Abstract    

    Abstract available

  141. MENG X, Press B, Renson A, Wysock JS, et al
    Discriminative Ability of Commonly Used Indexes to Predict Adverse Outcomes After Radical Cystectomy: Comparison of Demographic Data, American Society of Anesthesiologists, Modified Charlson Comorbidity Index, and Modified Frailty Index.
    Clin Genitourin Cancer. 2018;16:e843-e850.
    Abstract    

    Abstract available

  142. HENSLEY PJ, Goodwin J, Davenport DL, Strup SE, et al
    Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2018;16:e851-e858.
    Abstract    

    Abstract available

  143. BREYER J, Wirtz RM, Erben P, Worst TS, et al
    High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Clin Genitourin Cancer. 2018;16:248-256.
    Abstract    

    Abstract available

  144. LORENTZ CA, Gilbert K, Alemozaffar M, Patil D, et al
    Risk of Readmission After Uncomplicated Hospitalization After Radical Cystectomy.
    Clin Genitourin Cancer. 2018;16:e705-e710.
    Abstract    

    Abstract available

  145. HEMDAN T, Turker P, Malmstrom PU, Segersten U, et al
    Choline-phosphate cytidylyltransferase-alpha as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder.
    Scand J Urol. 2018;52:200-205.
    Abstract    

    Abstract available

  146. POWLES T, Necchi A, Rosen G, Hariharan S, et al
    Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Clin Genitourin Cancer. 2018;16:117-129.
    Abstract    

    Abstract available

  147. LIU ST, Hui G, Mathis C, Chamie K, et al
    The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Clin Genitourin Cancer. 2018;16:e269-e276.
    Abstract    

    Abstract available

  148. GUPTA S, Albertson D, Gaston D, Heilbrun ME, et al
    Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.
    Clin Genitourin Cancer. 2018;16:e373-e382.
    Abstract    

    Abstract available

  149. MIRSADRAEI L, Hodkoff A, Jones K, Shabaik A, et al
    Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
    Arch Pathol Lab Med. 2018;142:168-177.
    Abstract    

    Abstract available

  150. PEDERSEN M, Stafoggia M, Weinmayr G, Andersen ZJ, et al
    Is There an Association Between Ambient Air Pollution and Bladder Cancer Incidence? Analysis of 15 European Cohorts.
    Eur Urol Focus. 2018;4:113-120.
    Abstract    

    Abstract available

  151. KUSUHARA Y, Daizumoto K, Kawai K, Hirayama K, et al
    Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer.
    Anticancer Res. 2019;39:703-711.
    Abstract    

    Abstract available

  152. TAN WS, Teo CH, Chan D, Heinrich M, et al
    Mix methods approach to explore patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy in bladder cancer surveillance.
    BJU Int. 2019 Jan 29. doi: 10.1111/bju.14690.
    Abstract    

    Abstract available

  153. MMEJE CO, Benson CR, Nogueras-Gonzalez GM, Jayaratna IS, et al
    Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.
    BJU Int. 2018;122:89-98.
    Abstract    

    Abstract available

  154. JEFFERIES ER, Cresswell J, McGrath JS, Miller C, et al
    Open radical cystectomy in England: the current standard of care - an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data.
    BJU Int. 2018;121:880-885.
    Abstract    

    Abstract available

  155. HUGAR LA, Lopa SH, Yabes JG, Yu JA, et al
    Palliative Care Use Among Patients with Bladder Cancer.
    BJU Int. 2019 Feb 13. doi: 10.1111/bju.14708.
    Abstract    

    Abstract available

  156. BRASSETTI A, Moller A, Laurin O, Hoijer J, et al
    Evolution of cystectomy care over an 11-year period in a high-volume tertiary referral centre.
    BJU Int. 2018;121:752-757.
    Abstract    

    Abstract available

  157. DUFOUR F, Silina L, Neyret-Kahn H, Moreno-Vega A, et al
    TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
    Br J Cancer. 2019 Feb 15. pii: 10.1038/s41416-019-0397.
    Abstract    

    Abstract available

  158. NASER-TAVAKOLIAN A, Ghodoussipour S, Djaladat H
    Upper urinary tract recurrence following bladder cancer therapy: a review of surveillance and management.
    Curr Opin Urol. 2019 Feb 11. doi: 10.1097/MOU.0000000000000598.
    Abstract    

    Abstract available

  159. MUKHERJEE N, Wheeler KM, Svatek RS
    Bacillus Calmette-Guerin treatment of bladder cancer: a systematic review and commentary on recent publications.
    Curr Opin Urol. 2019 Feb 11. doi: 10.1097/MOU.0000000000000595.
    Abstract    

    Abstract available

  160. NECCHI A, Raggi D, Giannatempo P, Alessi A, et al
    Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
    Eur J Cancer. 2018;96:128-130.
    Abstract    



  161. CHOUDHURY A, Hoskin PJ
    Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues.
    Eur Urol. 2019 Feb 4. pii: S0302-2838(19)30086.
    Abstract    



  162. EFSTATHIOU JA, Mouw KW, Gibb EA, Liu Y, et al
    Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30012.
    Abstract    

    Abstract available

  163. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30075.
    Abstract    



  164. RADZISZEWSKI P, Poletajew S
    Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-G
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30074.
    Abstract    



  165. VOGELZANG NJ
    Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?
    Eur Urol. 2018;74:754-755.
    Abstract    



  166. GOLDSTEIN MR, Mascitelli L
    Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.008.
    Eur Urol. 2019 Feb 11. pii: S0302-2838(19)30093.
    Abstract    



  167. KAMAT AM, Li R, O'Donnell MA, Black PC, et al
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We There Yet? A Systematic Review.
    Eur Urol. 2018;73:738-748.
    Abstract    

    Abstract available

  168. KOIE T, Ohyama C, Makiyama K, Shimazui T, et al
    Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13900.
    Abstract    

    Abstract available

  169. TEISHIMA J, Matsubara A
    Editorial Comment to Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13906.
    Abstract    



  170. AMINI E, Ahmadi N, Clifford TG, Hugen CM, et al
    Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.
    Int Urol Nephrol. 2019 Jan 31. pii: 10.1007/s11255-019-02087.
    Abstract    

    Abstract available

  171. HAIFLER M
    Editorial Comment.
    J Urol. 2018;200:59-60.
    Abstract    



  172. FILSON CP
    Editorial Comment.
    J Urol. 2018;200:59.
    Abstract    



  173. MEEKS JJ, Glaser AP
    Editorial Comment.
    J Urol. 2018;200:60.
    Abstract    



  174. WANG DS
    Re: A Prospective Randomized Pilot Study Evaluating an ERAS Protocol versus a Standard Protocol for Patients Treated with Radical Cystectomy and Urinary Diversion for Bladder Cancer.
    J Urol. 2019 Feb 1. doi: 10.1097/JU.0000000000000154.
    Abstract    



  175. CHANG SS
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
    J Urol. 2019;201:442.
    Abstract    



  176. CHANG SS
    Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer.
    J Urol. 2019;201:441-442.
    Abstract    



  177. CHANG SS
    Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer.
    J Urol. 2019;201:441.
    Abstract    



  178. GRIEBLING TL
    Re: Impact of Psychiatric Illness on Decreased Survival in Elderly Patients with Bladder Cancer in the United States.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000162.
    Abstract    



  179. GRIEBLING TL
    Re: Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553996.66966.
    Abstract    



  180. GRIEBLING TL
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553995.59343.
    Abstract    



  181. CHANG SS
    Re: Predicting Local Failure after Radical Cystectomy in Patients with Bladder Cancer: .
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000166.
    Abstract    



  182. CHANG SS
    Re: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554054.35801.
    Abstract    



  183. CHANG SS
    Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554055.35801.
    Abstract    



  184. KIMURA S, Mari A, Foerster B, Abufaraj M, et al
    Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:46-53.
    Abstract    

    Abstract available

  185. ROUDNICKY F, Yoon SY, Poghosyan S, Schwager S, et al
    Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels.
    Oncogene. 2018;37:2573-2585.
    Abstract    

    Abstract available

  186. MARTIN T, Mantey K, Boissier R, Albert P, et al
    [The REVELA13 observatory to study new cases of bladder tumor among women living in Bouches-du-Rhone county].
    Prog Urol. 2018;28:935-941.
    Abstract    

    Abstract available

  187. BALDINI A, Fassi Fehri H, Cerantola Y, Bayle F, et al
    [Do initial experience with an enhanced recovery program after surgery (ERAS) improve postoperative outcomes after cystectomy?]
    Prog Urol. 2018;28:351-358.
    Abstract    

    Abstract available

  188. GROEBEN C, Koch R, Baunacke M, Borkowetz A, et al
    In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014.
    Urol Int. 2019 Jan 30:1-9. doi: 10.1159/000496347.
    Abstract    

    Abstract available

  189. MOSCHINI M, Zamboni S, Mattei A, Baumeister P, et al
    Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Urol Int. 2019 Jan 29:1-8. doi: 10.1159/000493899.
    Abstract    

    Abstract available

  190. GOULET CR, Champagne A, Bernard G, Vandal D, et al
    Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
    BMC Cancer. 2019;19:137.
    Abstract    

    Abstract available

  191. BOSSCHIETER J, Bach S, Bijnsdorp IV, Segerink LI, et al
    A protocol for urine collection and storage prior to DNA methylation analysis.
    PLoS One. 2018;13:e0200906.
    Abstract    

    Abstract available

  192. HASNAIN Z, Mason J, Gill K, Miranda G, et al
    Machine learning models for predicting post-cystectomy recurrence and survival in bladder cancer patients.
    PLoS One. 2019;14:e0210976.
    Abstract    

    Abstract available

  193. LIM YW, Chen-Harris H, Mayba O, Lianoglou S, et al
    Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration.
    Proc Natl Acad Sci U S A. 2018;115:E11701-E11710.
    Abstract    

    Abstract available

  194. MULLENDERS J, de Jongh E, Brousali A, Roosen M, et al
    Mouse and human urothelial cancer organoids: A tool for bladder cancer research.
    Proc Natl Acad Sci U S A. 2019 Feb 20. pii: 1803595116.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;